Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072059 · ClinicalTrials.gov registry record · Phase 2
Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00072059 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center.
The verdict
NCT00072059, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Ro 50-3821 may stimulate red blood cell production and treat anemia in patients who are receiving antineoplastic therapy for non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying six different regimens of Ro 50-3821 to compare how well they work in treating anemia in patients who are receiving antineoplastic therapy for stage IIIB or stage IV non-small cell lung cancer.
Interventions
- BIOLOGICAL methoxy polyethylene glycol epoetin beta
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-07 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072059
The ClinicalTrials.gov registry entry for NCT00072059 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which methoxy polyethylene glycol epoetin beta is the first listed.
NCT00072059 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072059 about?
NCT00072059 is a clinical study titled "Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Ro 50-3821 may stimulate red blood cell production and treat anemia in patients who are receiving antineoplastic therapy for non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying six different regimens of Ro 50-3821 to compare how well they work in treating anem...
What is the current status of trial NCT00072059?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-07. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00072059?
The interventions under investigation include: methoxy polyethylene glycol epoetin beta (BIOLOGICAL).
Who is sponsoring clinical trial NCT00072059?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.